BKM120 in Esophageal Squamous Cell Carcinoma After Failure of First Line Chemotherapy
Status:
Terminated
Trial end date:
2016-04-30
Target enrollment:
Participant gender:
Summary
There is a need for more effective therapy for patients with esophageal squamous cell
carcinoma who developed disease progression after first line therapy. Currently, there is no
standard second-line therapy for this disease.
BKM-120 is a pan-PI3K inhibitor currently tested in clinical trials. In a cellular model of
oral-esophageal carcinogenesis, it has shown that EGFR overexpression activated PI3/AKT
pathway. Therfore, there is interest to see the efficacy and safety of BKM120 in this
setting.